In the realm of longevity research, Nicotinamide Mononucleotide (NMN) has emerged as a promising compound with potential health-enhancing properties. A groundbreaking NMN clinical trial, conducted by Wonderfeel in collaboration with Abinopharm, has recently provided compelling insights into NMN's impact on human health.
The Trial's Parameters
This comprehensive NMN clinical trial involved 80 participants aged 40 to 65, grouped into four categories: placebo, 300 mg, 600 mg, and 900 mg of NMN administered daily. The study aimed to assess NMN's effects on NAD levels in the blood, endurance in a six-minute walking test, and overall health scores measured by the SF-36 questionnaire. Preliminary findings confirm NMN's effectiveness in raising NAD levels and significantly improving the health scores of participants, underlining the importance of dosing.
Mean vs. Median
While the study primarily focused on mean averages in its analysis, our examination of the raw data reveals that interpreting results through median averages offers a more accurate perspective.
Interpreting Results of the NMN Clinical Trial
Comparing mean and median averages for NMN's impact on NAD levels and health scores yields intriguing results:
-
For NAD levels, the mean improvement percentages suggest that the 600 mg group is the most effective. However, when considering median averages, the 900 mg group outperforms the rest, although the difference isn't statistically significant compared to the 600 mg group.
-
Analysing health score improvements, mean averages indicate the 600 mg group as the leader. Yet, when viewed through median averages, the 900 mg group shows slightly better results.
Conclusion
In conclusion, the latest NMN clinical trial showcases NMN's potential to enhance human health. Examining data through median averages reveals that higher dosages, particularly 900 mg, may offer the most substantial benefits. This underscores the importance of meticulous data interpretation and highlights the need for further research in the field of longevity.
As we eagerly await more extensive studies, it's clear that exploring trial data from multiple angles, with a focus on median averages, can unearth valuable insights. NMN continues to be a beacon of hope for those seeking improved health and longevity.
If you would like to see the full study report we've included the link below:
https://getwonderfeel.com/human-clinical-trial-nmn/?utm_source=LongevityTech&utm_medium=article&utm_campaign=NMN2023